12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pradaxa regulatory update

FDA said it is reviewing postmarketing reports of serious bleeding events in patients receiving atrial fibrillation (AF) drug Pradaxa dabigatran etexilate from Boehringer. The agency said it believes that the direct oral thrombin inhibitor...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >